Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance

Atherosclerosis

Volumn 230, Issue 1, 2013, Pages 121-124

  Ballard, Kevin D ^a   Parker, Beth A ^a   Capizzi, Jeffrey A ^a   Grimaldi, Adam S ^a   Clarkson, Priscilla M ^b   Cole, Stephanie M ^b   Keadle, Justin ^b   Chipkin, Stuart ^b   Pescatello, Linda S ^c   Simpson, Kathleen ^c   White, C Michael ^c   Thompson, Paul D ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Exercise; Muscle; Myalgia; Statins

Indexed keywords

ATORVASTATIN; CREATINE KINASE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; EXERCISE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MUSCLE FUNCTION; MYALGIA; NORMAL HUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; TREATMENT DURATION;

EXERCISE; MUSCLE; MYALGIA; STATINS;

ADULT; CREATINE KINASE; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCLES; MYALGIA; PYRROLES; TREATMENT OUTCOME;

EID: 84881632814     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.07.001     Document Type: Article

References (24)

1. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359:2195-2207.
2. Parker B.A., Capizzi J.A., Grimaldi A.S., Clarkson P.M., Cole S.M., Keadle J., et al. Effect of statins on skeletal muscle function. Circulation 2013, 127:96-103.
3. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8mmol/liter (200 to 300mg/dl) plus two additional atherosclerotic risk factors. The pravastatin multinational study group for cardiac risk patients. Am J Cardiol 1993, 72:1031-1037.
4. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C.A., Franklin F.A., Grillo R.B., et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994, 74:667-673.
5. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
6. Maningat P., Breslow J.L. Needed: pragmatic clinical trials for statin-intolerant patients. NEngl J Med 2011, 365:2250-2251.
7. Pitt B., Mancini G.B., Ellis S.G., Rosman H.S., Park J.S., McGovern M.E. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. JAm Coll Cardiol 1995, 26:1133-1139.
8. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 287:3215-3222.
9. Serruys P.W., Foley D.P., Jackson G., Bonnier H., Macaya C., Vrolix M., et al. Arandomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999, 20:58-69.
10. Parker B.A., Augeri A.L., Capizzi J.A., Ballard K.D., Troyanos C., Baggish A.L., et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol 2012, 109:282-287.
11. Thompson P.D., Zmuda J.M., Domalik L.J., Zimet R.J., Staggers J., Guyton J.R. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997, 46:1206-1210.
12. Ganga HV, Slim J and Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Unpublished work.
13. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin multicenter study group II. Arch Intern Med 1993, 153:1321-1329.
14. Keech A., Collins R., MacMahon S., Armitage J., Lawson A., Wallendszus K., et al. Three-year follow-up of the oxford cholesterol study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994, 15:255-269.
15. Pedersen T.R., Berg K., Cook T.J., Faergeman O., Haghfelt T., Kjekshus J., et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian simvastatin survival study. Arch Intern Med 1996, 156:2085-2092.
16. Swaminathan R., Ho C.S., Donnan S.P. Body composition and plasma creatine kinase activity. Ann Clin Biochem 1988, 25(Pt 4):389-391.
17. Lee Y.H., Choi S.J., Ji J.D., Song G.G. Serum creatine kinase in patients with rheumatic diseases. Clin Rheumatol 2000, 19:296-300.
18. Dichtl W., Dulak J., Frick M., Alber H.F., Schwarzacher S.P., Ares M.P., et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003, 23:58-63.
19. Clarkson P.M., Hoffman E.P., Zambraski E., Gordish-Dressman H., Kearns A., Hubal M., et al. ACTN3 and MLCK genotype associations with exertional muscle damage. JAppl Physiol 2005, 99:564-569.
20. Hubal M.J., Devaney J.M., Hoffman E.P., Zambraski E.J., Gordish-Dressman H., Kearns A.K., et al. CCL2 and CCR2 polymorphisms are associated with markers of exercise-induced skeletal muscle damage. JAppl Physiol 2010, 108:1651-1658.
21. Ghatak A., Faheem O., Thompson P.D. The genetics of statin-induced myopathy. Atherosclerosis 2010, 210:337-343.
22. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581-585.
23. Soininen K., Niemi M., Kilkki E., Strandberg T., Kivisto K.T. Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol 2006, 98:51-54.
24. Mohaupt M.G., Karas R.H., Babiychuk E.B., Sanchez-Freire V., Monastyrskaya K., Iyer L., et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009, 181:E11-E18.